Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Characterization of soman toxicity in atropine and oxime (Hi-6 and MMB-4) treated rhesus monkeys

Technical Report ·
OSTI ID:7043517

There is a need for improved therapeutic compounds, specifically oximes, for humans exposed to organophosphorus (OP) anticholinesterase agents. Although pyridine-2-aldoxime (pralidoxime chloride; 2-PAM), the standard therapeutic oxime, is effective for treating exposure to certain OPs, it is only a marginally effective treatment for intoxications produced by other OPs such as pinacolylmethylphosphonofluoridate (soman; GD). Two bispyridinium oximes, HI-6 and MMB-4, have been suggested as replacements for 2-PAM in the treatment of OP intoxications in man. A study was conducted at Battelle's Medical Research and Evaluation Facility to determine the efficacies of HI-6 and MMB-4, given with atropine, in alleviating the signs of GD intoxication in monkeys. Treatments were administered 1 min after GD injection using a demonstrated efficacious dose of 0.4 mg atropine free base per kilogram of body weight, and 100 umol/kg of either candidate oxime. Although there is not a complete understanding of mechanism(s) of action, HI-6 proved more efficacious than MMB-4 in preventing lethality and in decreasing duration of clinical signs of GD intoxication.

Research Organization:
Battelle Memorial Inst., Columbus, OH (United States)
OSTI ID:
7043517
Report Number(s):
AD-P-008815/3/XAB; CNN: DAMD17-89-C-9050
Country of Publication:
United States
Language:
English